<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450813</url>
  </required_header>
  <id_info>
    <org_study_id>COVMOPR0176</org_study_id>
    <nct_id>NCT01450813</nct_id>
  </id_info>
  <brief_title>The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy</brief_title>
  <official_title>The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Bispectral Index (BIS) monitor is used in many operating rooms to provide information to
      the anesthesiologist about a patient's level of consciousness. The Composite Variability
      Index (CVI) is a new index that may provide the anesthesiologist with more information about
      the condition of the patient. The CVI is a measure of the combined variability in BIS
      (bispectral index) and frontal electromyography (EMG) activity that may be useful in
      assessing the nociception/anti-nociception balance for patients under general anesthesia.The
      purpose of this study is to determine if a commonly used anesthetic drug (rocuronium) affects
      the CVI measurement differently with different doses. Rocuronium is a neuromuscular blocking
      agent (NMBA) routinely used during surgery. It is expected that the group given the highest
      dose of rocuronium will have diminished CVI values.

      This study will randomize patients to one of four doses of rocuronium: no rocuronium, 0.2,
      0.4, and 0.6 milligrams per kilo of body weight; the last dose is the standard amount for
      adults. It is expected that the group given the highest dose of rocuronium will have
      diminished CVI values. By including intermediate doses, information about the function of CVI
      in states of less than full muscle relaxation, or paralysis, will be obtained. This
      information is critically important for the development of the composite variability index,
      because during general anesthesia patients are usually maintained in a state of less than
      full paralysis. If the CVI response to stimulation in the intermediate groups is similar to
      the group receiving no rocuronium, the monitor may find wide clinical applicability. If the
      response is similar to the maximal rocuronium group, the index may only be reliable in states
      with no muscle relaxant, which will greatly limit clinical utility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consented subjects randomized to one of four doses of rocuronium will be transported to the
      operating room and be connected to routine monitors that included a BIS (Covidien), M-Entropy
      sensor (GE Healthcare) and TOF (train of four) monitor. Following preoxygenation, general
      anesthesia will be induced with propofol and remifentanil using traditional syringe pumps.
      The induction doses given and subsequent infusion rates will be determined by utilizing
      pharmacokinetic (Pk) models (Marsh model for propofol, Minto model for remifentanil).
      Unconsciousness will be confirmed by performing the usual clinical assessments and by
      obtaining a BIS value between 40 and 50. Once the subject is unconsciousness, they will be
      given the assigned dose of rocuronium, after which the study anesthesiologist will perform a
      laryngoscopy. The anesthesiologist performing the laryngoscopy will not know what dose of
      rocuronium the subject received. Neuromuscular blockade (NMB) will be monitored by a
      train-of-four twitch monitor (TOF Watch-SX) at the adductor pollicis muscle (2 HZ, 50mAmp)
      every 15 seconds.

      At three minutes after the rocuronium administration, a standardized 20-second laryngoscopy
      will be applied. The CVI, entropy, and hemodynamic responses (heart rate, blood pressure
      measurement each minute) and train-of-four measurements will be monitored for three minutes
      before and after the laryngoscopy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups</measure>
    <time_frame>Six minutes after the dose of rocuronium with laryngoscopy at 3 minutes after the study intervention</time_frame>
    <description>The difference between the mean CVI in three minutes prior to laryngoscopy and three minutes following laryngoscopy reported as the mean change in CVI and the +/- 95% confidence interval for each group.
The Composite Variability Index (CVI) scale is a logistic regression of three measures of processed electroencephalography (EEG) signals. These signals are Bispectral Index (BIS), the variability of electromyelogram (sEMG), and the variability of BIS (sBIS). The scale ranges from 0 to 100 where a lower CVI value represents a lower likelihood of intraoperative somatic responses, and a higher CVI value represents a higher likelihood of intraoperative somatic responses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups</measure>
    <time_frame>Maintenance Anesthesia</time_frame>
    <description>Mean CVI from incision to propofol off reported as the mean CVI +/- 95% confidence interval for the two groups</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Anesthesia</condition>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Saline 0.06 ml/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium 0.2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium 0.4 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium 0.6 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.06 ml/kg</intervention_name>
    <description>IV Infusion x1 prior to laryngoscopy</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0.2 mg/kg</intervention_name>
    <description>IV Infusion x1 prior to laryngoscopy</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0.4 mg/kg</intervention_name>
    <description>IV Infusion x1 prior to laryngoscopy</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0.6 mg/kg</intervention_name>
    <description>IV Infusion x1 prior to laryngoscopy</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesia (ASA) physical status class I or II.

          -  Body mass index between 18 and 35 kg m-2.

          -  No use of psychotropic or neuropsychiatric medications.

          -  A airway assessment with no indication of a difficult intubation including a class I
             or II Mallampati airway and a mandible-to-hyoid distance of greater than three
             fingerbreadths.

          -  Age between 18-75 years.

        Exclusion Criteria:

          -  Does not meet inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald M Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <results_first_submitted>March 10, 2016</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data collected was for device algorithm development</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Saline 0.06 ml/kg</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Rocuronium 0.2 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Rocuronium 0.4 mg/kg</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Rocuronium 0.6 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Rocuronium dose 0 mg/kg prior to laryngoscopy</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Rocuronium dose 0.2 mg/kg prior to laryngoscopy</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Rocuronium dose 0.4 mg/kg prior to laryngoscopy</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Rocuronium dose 0.6 mg/kg prior to laryngoscopy</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="12.3"/>
                    <measurement group_id="B2" value="38.6" spread="14.6"/>
                    <measurement group_id="B3" value="39.4" spread="12.7"/>
                    <measurement group_id="B4" value="32.9" spread="6.4"/>
                    <measurement group_id="B5" value="37.9" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups</title>
        <description>The difference between the mean CVI in three minutes prior to laryngoscopy and three minutes following laryngoscopy reported as the mean change in CVI and the +/- 95% confidence interval for each group.
The Composite Variability Index (CVI) scale is a logistic regression of three measures of processed electroencephalography (EEG) signals. These signals are Bispectral Index (BIS), the variability of electromyelogram (sEMG), and the variability of BIS (sBIS). The scale ranges from 0 to 100 where a lower CVI value represents a lower likelihood of intraoperative somatic responses, and a higher CVI value represents a higher likelihood of intraoperative somatic responses.</description>
        <time_frame>Six minutes after the dose of rocuronium with laryngoscopy at 3 minutes after the study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Rocuronium 0mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Rocuronium 0.2mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Rocuronium 0.4mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Rocuronium 0.6mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups</title>
          <description>The difference between the mean CVI in three minutes prior to laryngoscopy and three minutes following laryngoscopy reported as the mean change in CVI and the +/- 95% confidence interval for each group.
The Composite Variability Index (CVI) scale is a logistic regression of three measures of processed electroencephalography (EEG) signals. These signals are Bispectral Index (BIS), the variability of electromyelogram (sEMG), and the variability of BIS (sBIS). The scale ranges from 0 to 100 where a lower CVI value represents a lower likelihood of intraoperative somatic responses, and a higher CVI value represents a higher likelihood of intraoperative somatic responses.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" lower_limit="2.15" upper_limit="2.64"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.95" upper_limit="1.83"/>
                    <measurement group_id="O3" value="0.48" lower_limit="0.24" upper_limit="0.72"/>
                    <measurement group_id="O4" value="0.17" lower_limit="-0.04" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis that neuromuscular blocking drugs have no effect on CVI with 95% confidence.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size needed for a one-way ANOVA test with an alpha of 0.05 and power of 0.8 to rule out the null hypothesis that neuromuscular blocking drugs have no effect on CVI with 95% confidence was a total of 64 or 16 per Group.</non_inferiority_desc>
            <p_value>&lt; 0.05</p_value>
            <p_value_desc>Comparisons of the means were accomplished via student's t-test with Bonferroni correction for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups</title>
        <description>Mean CVI from incision to propofol off reported as the mean CVI +/- 95% confidence interval for the two groups</description>
        <time_frame>Maintenance Anesthesia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remifentanil 2ng/ml</title>
            <description>The anesthesia provider will titrate propofol as appropriate throughout the procedure to maintain a BIS level between 45- 60.</description>
          </group>
          <group group_id="O2">
            <title>Remifentanil 8 ng/ml</title>
            <description>The anesthesia provider will titrate propofol as appropriate throughout the procedure to maintain a BIS level between 45- 60.</description>
          </group>
        </group_list>
        <measure>
          <title>The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups</title>
          <description>Mean CVI from incision to propofol off reported as the mean CVI +/- 95% confidence interval for the two groups</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.56" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.38" lower_limit="1.31" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Response to mediations for laryngoscopy in the operating room</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Rocuronium dose 0 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Rocuronium dose 0.2 mg/kg</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Rocuronium dose 0.4 mg/kg</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>Rocuronium dose 0.6 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size for this study calculation was based upon the assumption that that the expected mean of CVI would be 60 with a variance of 30 and that the variance of 30 would be equal for each group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Donald Mathews, M.D.</name_or_title>
      <organization>Fletcher Allen Health Care at The University of Vermont</organization>
      <phone>(802) 847-2415</phone>
      <email>Donald.Mathews@vtmednet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

